You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    Summary: The ultimate goal of this Phase II application is to develop novel small molecule, broad-spectrum therapeutics against viral infections caused by filoviruses, arenaviruses, and other viruses that depend on the PPxY L-domain motif for egress and spread of infection. Some of these viruses, including Ebola (EBOV), Marburg (MARV), and Lassa fever (LAFV) viruses, are highly pathogenic and clas ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    Recent advances in technology have made possible the treatment of a growing number of structural cardiovascular diseases by catheter based procedures. Atrial septal defects (ASD), ventricular septal defects (VSD), aortic aneurysm, congenital defects and valve disease are all currently being treated with catheter based strategies. These procedures are complex and are prone to device misplacement, e ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. IND enabling development of LGM2605 as adjuvant treatment for asthma

    SBC: Lignamed, LLC            Topic: NIAID

    Project summary IND enabling development of LGM2605 as adjuvant treatment for asthma Glucocorticoid resistance is a major treatment problem in asthma. Our recent studies in mice, non-human primates and severe asthma patients, along with reports by others suggest that glucocorticoid receptor (GR) expression was impaired by psychosocial stress, in association with enhanced NF-kB activation and gluco ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction

    SBC: FREEFLOW MEDICAL DEVICES LLC            Topic: 106

    PROJECT SUMMARY Hydrocephalus causes long term neurological problems and patient suffering. Current treatments, most of which involve surgical diversion of cerebrospinal fluid (CSF) with shunt catheters, fail at an alarming rate. Approximately 98% of all shunts fail within 10 years, and this failure rate is the dominant contributor to the $2 billion-per-year cost that hydrocephalus incurs on our h ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Universal Brain Atlas for Implanting and Managing Deep Brain Stimulators

    SBC: Neurotargeting, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Deep brain stimulation has risen as a neurosurgical procedure of choice for patients with disabling neurological or psychiatric disorders for its abiliy to modulate improvement in the activity of certain circuits. The procedure is currently approved for treatment of Parkinson's disease (PD), essential tremor (ET), dystonia, and obsessive-compulsive disorde ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as t he symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer’s disease (AD) and related dementias are increasing rapidly yet, remarkably, there are no approved disease modifying drugs. Virtually all trials targeting amyloid related pathways have failed over the last 10 years. Regrettably, few alternative targets or pathways have been explored. Therefore, there is an urgent need to explore alternative pathways as monotherapies or as cons ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, although there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances i ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    AbstractProject Summary Cognition Therapeutics IncsCogrxmission is to develop effective therapeutics for Alzheimer s diseaseADOligomers of the brain protein Amyloid betaA Oshave been identified as toxic components that are involved with disease progressionCognition has identified a subset of sigmareceptor binding modulators that displaces A Os from synaptic receptor sites and clears them into the ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government